Deb Conrady
Senior Principal Scientist - Structural Biology C4 Therapeutics Inc
Deb Conrady is a seasoned structural biologist with over 15 years of experience advancing structure-based drug discovery across biotech and pharmaceutical organizations. Currently Senior Principal Scientist, Structural Biology at C4 Therapeutics, she has held scientific leadership roles at Blueprint Medicines, HotSpot Therapeutics, FogPharma, and UCB. Her expertise spans X-ray crystallography, cryo-electron microscopy, protein engineering, and structure-guided drug design. Throughout her career, Deb has contributed to the discovery and development of novel therapeutics by leveraging structural insights to address challenging biological targets, while leading multidisciplinary teams and driving innovation in translational research and early-stage drug discovery.
Seminars
- C4 Therapeutics’ Molecular Glue discovery platform has identified novel degrader hits for several targets of high therapeutic interest
- Structural characterization revealed several non-canonical binding modes, expanding the potential target space beyond the prototypic G- and RT-loop motifs
- Early structure enablement accelerated molecular glue development into potent degrader molecules with optimal properties for further drug development
Structural biology can provide powerful insights into molecular recognition and binding, but its greatest value comes when those insights are generated early enough and applied broadly enough to influence drug design. As discovery teams increasingly seek to use structures to improve not only binding but also stability, expression, and developability, the challenge is creating workflows that translate structural information into better molecules. Join structural biologists, medicinal chemists, computational scientists, and drug discovery leaders as they discuss how to maximise the impact of SBDD on candidate progression by:
- Bringing structural information earlier into discovery, examining how delays between chemistry and structural data can limit decision making and how teams can prioritize structures that have the greatest potential to influence molecular design
- Translating structural insights into broader molecular optimization, exploring how structural information can be used to improve affinity and binding while also informing stability, expression, and developability
- Connecting structure-guided design with candidate progression, discussing how structural and computational insights can be incorporated into hit prioritization, lead optimization, and candidate selection to deliver better molecules more efficiently
